Phase ll study of the adjunctive use of azacitidine in patients undergoing reduced intensity allogeneic transplantation in acute myeloid leukaemia and myelodysplasia

niversity of Birmingham (UK)0 个研究点目标入组 37 人开始时间: 2008年3月20日最近更新: 2022年4月19日

适应症

试验速览

•1. Patients (male and female) between the age of 18 - 65 years in whom allogeneic transplantation using a myeloablative conditioning regimen is contra-indicated
•2. Patients who fulfill the World Health Organization (WHO) criteria for AML or MDS
•3. Patients with a human leukocyte antigen (HLA) identical sibling or suitable matched unrelated donor
•4. Must give written informed consent and be able to comply with the protocol for the duration of the study

•1. Patients with contra-indications to receiving fludarabine or azacitidine
•2. Pregnant or lactating women or adults of reproductive potential not willing to use appropriate medically approved contraception during the trial and for 12 months post-azacitidine
•3. Any co-morbidity that in the investigators opinion will affect the patients participation in this study

发起方

niversity of Birmingham (UK)